NCT02665910

Multiple Doses Escalation Study of SHR0302 in Rheumatoid Arthritis (RA) Patients

A Phase I, Randomized, Placebo-Controlled, Multiple Doses Escalation Study to Investigate Safety, Pharmacokinetics and Pharmacodynamics of SHR0302 in Patients With RA

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 48 (estimated)
• Sponsor: Jiangsu HengRui Medicine Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Condition: Rheumatoid Arthritis Intervention: Drug: SHR0302; Drug: SHR0302 placebo comparator Phase: Phase 1 Study Type: Interventional Study Design: Treatment, Parallel Assignment, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Randomized

Conditions

• Rheumatoid Arthritis

Interventions

Type	Name	Description
DRUG	SHR0302	Oral tablets (1 mg, 5 mg, 10 mg)
DRUG	SHR0302 placebo comparator	Oral tablets (1 mg, 5 mg, 10 mg) (matching corresponding study medication)

Timeline

• Start date: 2016-05-01
• Primary completion: 2016-12-01
• First posted: 2016-01-28
• Last updated: 2016-04-19

Locations

1 site across 1 country: China